» Articles » PMID: 22848663

Hepatitis B Virus X Protein Upregulates MTOR Signaling Through IKKβ to Increase Cell Proliferation and VEGF Production in Hepatocellular Carcinoma

Overview
Journal PLoS One
Date 2012 Aug 1
PMID 22848663
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC), a major cause of cancer-related death in Southeast Asia, is frequently associated with hepatitis B virus (HBV) infection. HBV X protein (HBx), encoded by a viral non-structural gene, is a multifunctional regulator in HBV-associated tumor development. We investigated novel signaling pathways underlying HBx-induced liver tumorigenesis and found that the signaling pathway involving IκB kinase β (IKKβ), tuberous sclerosis complex 1 (TSC1), and mammalian target of rapamycin (mTOR) downstream effector S6 kinase (S6K1), was upregulated when HBx was overexpressed in hepatoma cells. HBx-induced S6K1 activation was reversed by IKKβ inhibitor Bay 11-7082 or silencing IKKβ expression using siRNA. HBx upregulated cell proliferation and vascular endothelial growth factor (VEGF) production, and these HBx-upregulated phenotypes were abolished by treatment with IKKβ inhibitor Bay 11-7082 or mTOR inhibitor rapamycin. The association of HBx-modulated IKKβ/mTOR/S6K1 signaling with liver tumorigenesis was verified in a HBx transgenic mouse model in which pIKKβ, pS6K1, and VEGF expression was found to be higher in cancerous than non-cancerous liver tissues. Furthermore, we also found that pIKKβ levels were strongly correlated with pTSC1 and pS6K1 levels in HBV-associated hepatoma tissue specimens taken from 95 patients, and that higher pIKKβ, pTSC1, and pS6K1 levels were correlated with a poor prognosis in these patients. Taken together, our findings demonstrate that HBx deregulates TSC1/mTOR signaling through IKKβ, which is crucially linked to HBV-associated HCC development.

Citing Articles

VEGF-Virus Interactions: Pathogenic Mechanisms and Therapeutic Applications.

Sanchez-Martinez C, Grueso E, Calvo-Lopez T, Martinez-Ortega J, Ruiz A, Almendral J Cells. 2024; 13(21.

PMID: 39513922 PMC: 11545703. DOI: 10.3390/cells13211815.


mTOR Signaling: Roles in Hepatitis B Virus Infection and Hepatocellular Carcinoma.

Mei L, Sun H, Yan Y, Ji H, Su Q, Chang L Int J Biol Sci. 2024; 20(11):4178-4189.

PMID: 39247820 PMC: 11379076. DOI: 10.7150/ijbs.95894.


Hepatitis B Virus-Encoded MicroRNA (HBV-miR-3) Inhibits FIH-1 Expression to Promote Tumor Angiogenesis in HBV-Related Hepatocellular Carcinoma.

Chen H, Cao D, Han N, Zhang M, Jiang W, Wang X J Hepatocell Carcinoma. 2024; 10:2337-2353.

PMID: 38163053 PMC: 10757782. DOI: 10.2147/JHC.S436926.


EZH2-mediated epigenetic silencing of tumor-suppressive let-7c/miR-99a cluster by hepatitis B virus X antigen enhances hepatocellular carcinoma progression and metastasis.

Wu C, Chien Y, Yen C, Wu J, Bai L, Yu Y Cancer Cell Int. 2023; 23(1):199.

PMID: 37689710 PMC: 10493019. DOI: 10.1186/s12935-023-03002-9.


Pathogenesis of Hepatocellular Carcinoma: The Interplay of Apoptosis and Autophagy.

Kouroumalis E, Tsomidis I, Voumvouraki A Biomedicines. 2023; 11(4).

PMID: 37189787 PMC: 10135776. DOI: 10.3390/biomedicines11041166.


References
1.
Kaido T, Uemoto S . Recent evidence in the treatment of small hepatocellular carcinoma. Hepatogastroenterology. 2008; 55(85):1460-2. View

2.
Clement J, Meloche S, Servant M . The IKK-related kinases: from innate immunity to oncogenesis. Cell Res. 2009; 18(9):889-99. DOI: 10.1038/cr.2008.273. View

3.
Lee D, Kuo H, Chen C, Hsu J, Chou C, Wei Y . IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. 2007; 130(3):440-55. DOI: 10.1016/j.cell.2007.05.058. View

4.
Lara-Pezzi E, Majano P, Gomez-Gonzalo M, Garcia-Monzon C, Moreno-Otero R, Levrero M . The hepatitis B virus X protein up-regulates tumor necrosis factor alpha gene expression in hepatocytes. Hepatology. 1998; 28(4):1013-21. DOI: 10.1002/hep.510280416. View

5.
Lucito R, Schneider R . Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C. J Virol. 1992; 66(2):983-91. PMC: 240800. DOI: 10.1128/JVI.66.2.983-991.1992. View